Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: A single-blind randomised placebo controlled trial
<p>Abstract</p> <p>Background</p> <p>Depression is prevalent in people with type 2 diabetes and affects both glycemic control and overall quality of life. The aim of this trial was to evaluate the effect of the antidepressant paroxetine on metabolic control, quality of...
Main Authors: | Wahlbeck Kristian, Paile-Hyvärinen Maria, Eriksson Johan G |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2003-05-01
|
Series: | BMC Family Practice |
Online Access: | http://www.biomedcentral.com/1471-2296/4/7 |
Similar Items
-
The effects of paroxetine and nefazodone on sleep: a placebo controlled trial.
by: Sharpley, A, et al.
Published: (1996) -
Paroxetine versus other anti-depressive agents for depression
by: Purgato, M, et al.
Published: (2014) -
Distribution of Plasma One-Carbon Metabolism Factors and Amino Acids Profile in Depression State Treated with Paroxetine: A Model Study
by: Reyhaneh Aghajani, et al.
Published: (2023-03-01) -
Magnitude of placebo response in clinical trials of paroxetine for vasomotor symptoms: a meta-analysis
by: Joshua R. Rhodes, et al.
Published: (2023-08-01) -
Neural correlates of PTSD in women with childhood sexual abuse with and without PTSD and response to paroxetine treatment: A placebo-controlled, double-blind trial
by: J. Douglas Bremner, et al.
Published: (2023-12-01)